APA citáció

Falchi Lorenzo, Nijland Marcel, Huang Huiqiang, Linton Kim M, Seymour John F, Tao Rong, . . . et al. (2026). Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): A global, open-label, randomised, phase 3 trial.

Chicago Style (17th ed.) Citation

Falchi Lorenzo, et al. Epcoritamab, Lenalidomide, and Rituximab Versus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1): A Global, Open-label, Randomised, Phase 3 Trial. 2026.

MLA idézés

Falchi Lorenzo, et al. Epcoritamab, Lenalidomide, and Rituximab Versus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1): A Global, Open-label, Randomised, Phase 3 Trial. 2026.